Roche's event on key data presented at the MDA Virtual Clinical & Scientific Conference 2021
Phase II/III SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy
Roche Neuroscience and Rare Disease franchise update
Paulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development
Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
Karl Mahler, Head of Investor Relations and Roche Group Planning

Please register to access the replay*

*Privacy notice

Live webcast replay

Roche has hosted a virtual event on Friday, 19th March 2021

Past IR Events
View more Events


Related links